EGFR and neoplasm: In this context, different combinations of cetuximab with immunotherapy have been evaluated and are ongoing to test the hypothesis that combining the inhibition of PD-1 with an anti-EGFR antibody can induce a more favorable immune tumor microenvironment and overcome PD-1 resistance; however, to date, these combinations have demonstrated limited activity.